

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Physical Activity Trails in an Urban Setting and Cardiovascular Disease Morbidity and Mortality: A Study Protocol for a Natural Experiment

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036602
Article Type:	Protocol
Date Submitted by the Author:	03-Jan-2020
Complete List of Authors:	Hobin, Erin; Dalla Lana School of Public Health, University of Toronto, Swanson, Anders; Winnipeg Trails Booth, Gillian; University of Toronto, Endocrinology and Metabolism Russell, Kelly; University of Manitoba, Pediatrics and Child Health Rosella, Laura; University of Toronto, Dalla Lana School of Public Health Smith, Brendan; University of Toronto, Dalla Lana School of Public Health Manley, Ed; University College London, The Bartlett Centre for Advanced Spatial Analysis (CASA) Isaranuwatthai, Wanrudee; University of Toronto Institute of Health Policy Management and Evaluation Whitehouse, Stephanie; City of Winnipeg, Active Transportation Brunton, Nicole; University of Manitoba Faculty of Health Sciences, Pediatrics and Child Health McGavock, Jonathan; University of Manitoba, Pediatrics
Keywords:	Ischaemic heart disease < CARDIOLOGY, EPIDEMIOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, SPORTS MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 Physical Activity Trails in an Urban Setting and Cardiovascular Disease Morbidity and  
5 Mortality: A Study Protocol for a Natural Experiment  
6  
7

8 Erin Hobin, PhD<sup>1</sup>, Anders Swanson<sup>2</sup>, Gillian L. Booth MD, MSc<sup>3</sup>, Kelly Russell PhD<sup>4,5</sup>, Laura  
9 Rosella PhD, MHSc<sup>6</sup>, Brendan Smith<sup>1</sup>, Ed Manley PhD<sup>7</sup>, Wanrudee Isaranuwatthai PhD<sup>3</sup>,  
10 Stephanie Whitehouse<sup>4,5,8</sup>, Nicole Brunton, MSc<sup>4,5,8</sup>, Jonathan McGavock\*, PhD<sup>4,5,8</sup>  
11  
12  
13  
14

15  
16 (1) Public Health Ontario (2) Winnipeg Trails Association; (3) MAP Centre for Urban Health  
17 Solutions, St. Michaels Hospital (4) Department of Pediatrics and Child Health, Max Rady Faculty  
18 of Health Sciences, University of Manitoba, (5) Children's Hospital Research Institute of  
19 Manitoba (6) Dalla Lana School of Public Health, University of Toronto. (7) The Bartlett Centre  
20 for Advanced Spatial Analysis, Faculty of the Built Environment, University College London (8)  
21 Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Research Theme at the  
22 Children's Hospital Research Institute of Manitoba.  
23  
24

25  
26 \*Corresponding Author

27 Jonathan McGavock, PhD

28 Associate Professor,

29 Department of Pediatrics and Child Health

30 Faculty of Health Sciences, University of Manitoba

31 511 JBRC. Children's Hospital Research Institute of Manitoba

32 715 McDermot Ave. Winnipeg, MB R3E 3P4

33 Phone: 1-204-480-1359

34 Email: [jmcgavock@chrim.ca](mailto:jmcgavock@chrim.ca)  
35  
36  
37

38 Sources of Funding: Canadian Institutes of Health Research (PJT-153449; CPP-137910) and the  
39 Heart and Stroke Foundation of Canada (G-17-0018638)  
40  
41  
42

43 Word Count: 3718

44 Figures: 1

45 Tables: 3  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

## Abstract

**Introduction:** Aspects of the built environment that support physical activity are associated with better population health outcomes. Few experimental data exist to support these observations. This protocol describes the study of the creation of urban trails on cardiovascular disease (CVD)-related morbidity and mortality in a large urban centre.

**Methods and Analysis:** Between 2008 and 2010, the city of Winnipeg Canada, built four, paved, multi-use (eg. cycling, walking, running), two-lane trails, that are 5-8km long and span ~60 neighbourhoods. Linking a population-based health data with census and environmental data, we will perform an interrupted time series analysis to assess the impact of this natural experiment on CVD-related morbidity and mortality among individuals 30-65 years of age residing within 400m-1200m of the trail. The primary outcome of interest is a composite measure of incident major adverse CVD events (i.e. CVD-related mortality, ischemic heart disease, stroke, congestive heart failure). The secondary outcome of interest is a composite measure of incident CVD-related risk factors (i.e. diabetes, hypertension, dyslipidemia). Outcomes will be assessed quarterly in the 10 years before the intervention and five years following the intervention, with a four year interruption. We will adjust analyses for differences in age, sex, ethnicity, immigration status, income, gentrification and other aspects of the built environment (i.e. greenspace, fitness/recreation centres, walkability). We will also assess trail use and trail user profiles using field data collection methods (Trial Registration: NCT04057417).

**Ethics and Dissemination:** Ethical approvals for the study have been granted by the Health Research Ethics Board at the University of Manitoba and the Health Information Privacy Committee within the Winnipeg Regional Health Authority. We have adopted an integrated knowledge translation approach. Information will be disseminated with public and government partners.

### Strengths and Limitations:

- We are relying on natural experiment consisting of the expansion of trails within an urban environment to test our research hypothesis.
- We have access to data for the entire urban population over a 20-year time frame, capturing all health-related end-points
- We are triangulating health outcome data with robust field data on trail use to describe the population impact of the trail expansion
- We cannot determine individual-level physical activity levels in persons living within intervention neighbourhoods
- We will not be able to capture individual-level trail use and therefore do not know what percentage of the population within each neighbourhood are using the trails

### Rationale

The built environment is at the interface of public and health policy<sup>1,2</sup>. Social scientists have explored the association between the environment and health for decades<sup>3</sup>, and a growing body of evidence show some aspects of the built environment are associated with cardiovascular disease (CVD)<sup>3</sup> and its preceding risk factors<sup>4-8</sup>. The favourable associations between aspects of the built environment and CVD-related health have been observed primarily through the promotion of physical activity.

Various elements of the built environment are associated with increased physical activity, particularly access to walkable neighbourhoods and green space, and the proximity of recreation facilities<sup>2,4</sup>. Importantly, individuals living in built environments that facilitate physical activity (e.g. greater access to walkable neighbourhoods and green space) display more favourable cardiovascular health profiles<sup>2,9,10</sup>. For example, individuals are 10-20% more likely to meet daily recommendations for physical activity and 5% less likely to have obesity for every incremental increase in access to recreational facilities, green space, and walkable neighbourhoods<sup>2,11</sup>. Conversely, individuals living in environments with more fast food outlets and fewer healthy food options are more likely to eat unhealthy food, and live with obesity or diabetes<sup>12,13</sup>. Based on these associations, changes to the built environment are projected to be a cost-effective population health intervention to promote physical activity and prevent CVD<sup>14,15</sup>. Unfortunately, there are limited studies of the built environment and CVD-related morbidity and mortality. Additionally, current evidence in this field largely draws on underpowered cross-sectional studies<sup>4,16</sup>. While associations between the built environment and health behaviours

1  
2  
3 seem robust, it remains unclear if changes to the built environment are associated with improved  
4 health outcomes. Accordingly, experimental data are needed to determine if, and the extent to  
5 which, changes to the built environment are associated with reduced CVD-related morbidity and  
6 mortality<sup>17-19</sup>.  
7  
8  
9

10  
11 Elements of the built environment that support physical activity include neighbourhood  
12 walkability, access to greenspace and proximity to fitness/recreation centres<sup>2</sup>. Urban multi-use  
13 trails are an additional, but poorly studied, aspect of the built environment that could support  
14 greater population-level daily physical activity<sup>20</sup>. Urban trails are multi-use protected areas for  
15 cycling alone or a combination of cycling, walking and running. They can be used to facilitate  
16 active transportation or a combination of active transport and recreational physical activity.  
17  
18 Despite widespread growth of trail networks in urban areas, they are not included in calculations  
19 of walkability within a neighbourhood<sup>21</sup>, and little information exists for their association with  
20 health outcomes.  
21  
22  
23  
24  
25

26  
27  
28 As randomized controlled trials are virtually impossible in this field, natural experiments  
29 provide the only feasible opportunity to generate experimental evidence to examine a potential  
30 causal link between the built environment and health outcomes. The most recent systematic  
31 review and meta-analysis investigating the influence of the built environment on health  
32 outcomes, found no experimental studies and none of the studies included disease-specific CVD  
33 or CVD-related outcome measures (i.e. mortality, myocardial infarction, and/or co-morbid  
34 conditions)<sup>9</sup>. Consistent with the results of observational studies examining associations between  
35 the built environment and health, the majority of natural experiments revealed improvements in  
36 more proximal measures of CVD, for example physical activity; however, there is no  
37 experimental evidence examining whether changes in the built environment lead to changes in  
38 CVD-related morbidity or mortality<sup>9</sup>.  
39  
40  
41  
42  
43  
44  
45  
46

47  
48 The current study describes the methods and protocol for a natural experimental study  
49 evaluating the impact of a large expansion of an urban trail network on CVD-related morbidity  
50 and mortality in a large urban centre in Canada.  
51  
52  
53  
54  
55  
56  
57

## Methods and Analysis

### *Study Aims and Hypotheses*

The primary objective of this natural experimental study is to capitalize on major changes to the built environment that occurred in Winnipeg, Canada between 2010 and 2014 to determine if a significant expansion of an urban trail network is associated with reduced CVD-related morbidity and mortality. The secondary aim of the study is to determine the cost-benefit ratio of this intervention compared to forecasted costs associated without the expansion of the urban trail network. The last aim of the study is to describe patterns of trail use and trail users during the intervention time period. Our primary study hypothesis is that an expansion of an urban trail network will reduce population-level CVD-related mortality and morbidity in neighbourhoods within 400-1200m of the new trail compared to neighbourhoods lying outside these boundaries.

### *Study Design*

The most robust approach to test this research hypothesis is a quasi-experimental interrupted time series analysis with a comparison condition. The proposed interrupted time series analysis is strengthened by the use of a social and health data repository that provides an opportunity to link census, social and health data for the entire population of the City of Winnipeg beginning in 1995<sup>22-27</sup>. Interrupted time series designs are considered the most valid quasi-experimental designs when a randomized controlled trial is not possible<sup>28,29</sup>. They are the preferred design for population health interventions or pragmatic experiments as they strengthen pre-post designs, particularly if an appropriate comparison condition is available<sup>28-30</sup>. This approach is considered the gold standard for a natural experiment, as it captures real-world changes in population-level health outcomes following large policy or practice changes<sup>31-34</sup> that can eventually inform changes in health systems.

Using population-level outcome data over a 20-year period (2000 – 2019), we will construct an interrupted time series with a comparison condition. We selected a 20-year time frame as it will provide ~60 data points (~40 before and ~20 after the intervention) to test for changes in the slopes of CVD-related morbidity and mortality between groups before and after the expansion of urban trails. This design will allow us to better control for biases that



1  
2  
3 accompany non-randomized study designs<sup>35-37</sup> such as (1) secular trends, which in this case may  
4 be changes in CVD rates that could be interpreted as intervention effects if comparison  
5 neighbourhoods were not available; (2) seasonal effects, as rates of CVD tend to be higher  
6 during winter months<sup>38</sup>; (3) duration of the intervention where trails may only be used in the first  
7 few months or years following construction and data collected in the year or two following the  
8 expansion would not have identified this effect; (4) random short-term fluctuations in CVD rates  
9 that may occur which do not reflect overall trends and can lead to biased intervention effect  
10 estimates if only a short time window is studied, and (5) autocorrelation where rates of CVD are  
11 likely to be associated between time points and between neighbourhoods. In addition to  
12 employing an interrupted time series design to minimize biases, we will employ a series of  
13 complimentary statistical features that include segmented time series regression techniques<sup>28,37</sup>  
14 and autoregressive integrated moving average models<sup>30,39</sup>. To improve comparability of  
15 treatment and comparison neighbourhoods, we will create balanced treatment and comparison  
16 groups using propensity score matching<sup>40</sup>.

### 27 28 *Study population*

29  
30  
31 This study will be conducted within the metropolitan area of Winnipeg, Manitoba,  
32 Canada's seventh largest urban centre. It is considered a slow growth city, relative to other major  
33 urban centres in Canada<sup>41</sup>. Winnipeg includes ~700,000 residents, representing >50% of the  
34 population of the province of Manitoba. Data from administrative health care databases within  
35 the Manitoba Centre for Health Policy (MCHP) will be used to derive population-level estimates  
36 of CVD and CVD-related co-morbid conditions as previously done<sup>42-44</sup>. Health information for  
37 local residents will be linked to dissemination-level data using individual postal codes. We will  
38 restrict the analyses to the adult population aged 30 to 65 years as previously done<sup>21</sup>, as CVD  
39 end-points are <1/10,000 among persons under 30 years in Manitoba<sup>42</sup>.

### 40 41 42 43 44 45 46 47 *Intervention group: Winnipeg urban trail network expansion*

48  
49  
50 In the Canadian context, an urban trail is a multi-use public path which creates an  
51 attractive transportation and leisure activity corridor through a built environment, used largely  
52 during the summer months<sup>45</sup>. Urban trails are an ideal component of the built environment to  
53 study with a quasi-experimental design and aggregated data. In contrast to more commonly  
54  
55  
56  
57

1  
2  
3 studied aspects of the built environment that promote physical activity (e.g. neighbourhood  
4 walkability, green space), trails are substantially easier to manipulate, as they require minimal  
5 space within the urban landscape and can affect a much larger segment of the urban population  
6 as they cross multiple neighbourhoods.  
7  
8  
9

10  
11 Between 2008 and 2010, the City of Winnipeg and Province of Manitoba invested \$25  
12 million to expand the infrastructure for leisure and transportation-based physical activity. Several  
13 mixed socio-economic neighbourhoods within Winnipeg were exposed to one of four new urban  
14 trails between 2008 and 2010, affecting roughly 250,000 residents within ~350 dissemination  
15 areas. Details of the greenways are provided in Table 1 and their location within the city are  
16 provided in Figure 1. The four multi-use urban trails are over five kilometers in length, paved,  
17 two lane paths that are cleared and maintained by the City of Winnipeg Department of  
18 Transportation 12 months of the year. They provide efficient and desirable trails for both active  
19 transportation and leisure physical activity. The majority of the population of Winnipeg do not  
20 live in dissemination areas that are within a reasonable distance to access the urban trails and  
21 therefore will be treated as the control condition. (Figure 1 – Map).  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 *Outcome measures*

32  
33  
34 The primary outcome measure will be a composite endpoint of incident CVD-related  
35 events including new hospital admissions for cardiac-related events (CVD-mortality, ischemic  
36 heart disease and stroke) and CVD-related co-morbidities (Table 2). ICD-9-CM codes will be  
37 used up to 1 April 2004 and ICD-10-CA codes afterwards for disease diagnosis (appendix, Table  
38 1). These end-points were selected as they represent the largest burden of CVD-related morbidity  
39 in Canada, are the most relevant to policy makers and most likely to be modified by increased  
40 physical activity levels. These outcomes are derived from validated algorithms, providing an  
41 extremely accurate and sensitive capture of end-points<sup>43,46</sup>. Heart failure and peripheral artery  
42 disease will not be included in the composite outcome as algorithms have yet to be validated in  
43 the repository. The secondary outcome measure will be CVD-related co-morbidities, including  
44 hypertension, diabetes and dyslipidemia, as they are more proximal outcomes associated with  
45 changes in physical activity levels<sup>1,2,21</sup> and therefore more likely to change within  
46 neighbourhoods during the relatively short time frame of this intervention (Table 2).  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

## Exploratory and Confounding Variables

### *Trail Usage*

Eco-Counter Dual Inductive Loop Zelts are automated cyclist counters that will be used to measure trail usage as an exploratory variable, between 2014 and 2019<sup>47</sup>. Zelts have been discussed as an acceptable and reliable research tool to capture trail use<sup>48</sup>. Zelts are comprised of a main unit and sensory wiring. The main unit includes a battery, Global System for Mobile (GSM) transmission device and counting unit buried in manholes on the outer edge of a trail. Zelt counters will be placed at ten locations across the five trail developments and will collect cyclist data for 24 hours/day, seven days per week. Data collected from Zelts are time stamped and automatically uploaded to Eco-Visio online software via cellular networks at 3:00 a.m. everyday.

### *Field data collection to survey trail users*

To determine trail user demographics, we will conduct two waves of intercept surveys among a convenience sample of ~1000 trail users, one wave in 2018 and one in 2019. Users will be asked to complete a brief survey to provide demographic information, self-reported trail usage and the perceived impact of usage on both their physical and mental health. These surveys will be designed to be completed in three to five minutes, to minimize participant burden and facilitate the collection of responses from the highest possible number of users. Demographic data will include self-identified gender and ethnicity, age group, residential postal code, newcomer status and annual household income. Analyses of these data will determine which, if any, specific groups experience disproportionate access to the trails. Usage data will outline typical weekly trail use (in terms of frequency, duration and types of activities), commute time to reach trail paths, and reasons for using the trail system. Survey collection will occur year-round when weather permits as either paper or technological survey instruments may not perform optimally in extreme winter conditions.

Survey participants will be asked to provide the first three digits of their postal code. This data will be used to geo-map the neighbourhoods of visiting users for each trail through dot density mapping techniques. Geo-maps will reflect the population distribution and demographic variation represented at each trail. Postal code data and produced geo-maps will also be

1  
2  
3 combined with City of Winnipeg Census data (2016) to provide insight into represented  
4 residential neighbourhood distributions for ethnicity and household income.  
5  
6

### 7 **Confounding Variables**

8  
9 A detailed list of confounding variables and their source are provided in Table 3.  
10

11  
12 *Socioeconomic status:* Household income will be determined by census data, which are  
13 publically available every five years. We will rely on data from the 2006 and 2016 surveys to  
14 assess household income. We will also rely on a validated continuous index of material and  
15 social deprivation (socio-economic factor index, SEFI), that is calculated for each dissemination  
16 area in the province of Manitoba and reflects neighbourhood-level socio-economic well being<sup>49</sup>.  
17  
18

### 19 *Gentrification*

20  
21  
22 Gentrification describes demographic changes that may occur in a community over time  
23 as individuals with a higher socioeconomic status move into lower socioeconomic areas<sup>50</sup>. Since  
24 socioeconomic status can have large implications for outcomes related to CVD<sup>51-53</sup>, diabetes<sup>51,54</sup>  
25 and mortality<sup>52,55</sup>, it will be important to account for gentrification within neighbourhoods. First,  
26 changes in property taxation between 2008 and 2018 assessed by the City of Winnipeg will be  
27 examined for each included neighbourhood to approximate increases or decreases in household  
28 value. Additionally, 2001 Canadian Census data and the 2016 National Household Survey data  
29 will be used to determine shifts in relevant indicators including poverty, education,  
30 unemployment rates, language barriers, average household income and ethnicity. Finally, data  
31 characterizing retail indicators will be obtained from DMTI Spatial Inc (2006 to 2016) to  
32 compare the number and ratio of specialty coffee houses versus coffee and doughnut shops per  
33 capita within neighbourhoods<sup>21</sup>. This will act as a surrogate variable representing demographic  
34 shifts in retail demands.  
35  
36

### 37 *Built Environment Determinants of Physical Activity*

38  
39  
40 The Canadian Urban Environmental Health Research Consortium (CANUE) is a multi-  
41 disciplinary collaboration of specialists focused on environmental exposures and population  
42 health.<sup>56</sup> CANUE integrates several population health databases and environmental exposure  
43 datasets into an openly available resource. From the CANUE dataset we will integrate examine  
44  
45  
46  
47  
48

1  
2  
3 several estimates of greenspace, including accessibility of green space, type of vegetation, tree  
4 canopy cover in control for access to greenspaces in the treatment and comparison and  
5 intervention neighbourhoods across Winnipeg via the 2016 ArcGIS survey. All these data will be  
6 treated as confounding and adjusted for in the final analyses. We will also assess neighbourhood  
7 walkability using CAN-ALE scores calculated from a GIS-based composite of population  
8 density, mixed land use, access to public transportation and street connectivity. Finally, we will  
9 estimate the number of fitness and recreation centres within three kilometres of each household.  
10  
11  
12  
13  
14  
15

16 **Patient and Public involvement:** Members of the public will be involved at several stages of  
17 the study. Members of the public were involved in developing the study design, in response to  
18 priorities established by a local organization (Winnipeg Trails Association) dedicated to  
19 supporting urban trails for physical activity. Members of the public will help with recruitment of  
20 trail users during field data collection and collect survey responses. This organization will also  
21 develop public and policy maker-friendly tools to disseminate results of the study via their social  
22 media platforms and at local meetings. The organization, represented by its executive director  
23 (AS), acted as a co-applicant on the grant and a collaborator throughout the project.  
24  
25  
26  
27  
28  
29  
30

### 31 **Power calculation and sample size**

32  
33

34 We have the advantage of leveraging a health data repository that includes the majority of  
35 residents in Winnipeg and captures all endpoints that occurred within each time point for  
36 residents in that neighbourhood. During the pre-intervention period (2006/07 and 2011/12),  
37 overall mortality, annual incident rates of ischemic heart, hypertension, and diabetes were nearly  
38 identical between treatment and comparison neighbourhoods<sup>42</sup>. The stability of outcome  
39 measures will facilitate the detection of small, but meaningful, changes in trends or absolute  
40 events within treatment neighbourhoods. Segmented regression with propensity score matching  
41 will be used to compare changes in event rates between treatment and comparison  
42 neighbourhoods. The goal of the propensity score matching will be to pair the approximately 60  
43 treated units (i.e. neighbourhoods) with approximately 60 randomly selected comparison units  
44 balanced on key covariates known to influence physical activity levels and CVD-related  
45 mortality and morbidity, (socioeconomic status [SES], age, ethnicity and walkability) permitting  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 analysis of data as if it arose from a randomized design<sup>57</sup>. Power analysis is based on a  
4 comparison of incidence rates in matched treated and comparison units.  
5  
6

7  
8 Sample size calculations for clustered count data, where treatment assignment is at the  
9 neighbourhood level and the outcome is an incidence rate (e.g. Poisson count), were used to  
10 estimate the minimal detectable effect size<sup>18</sup>. We applied the Hayes-Donner method to estimate  
11 the number of neighbourhoods required to discern a given effect size, expressed as the difference  
12 between group-specific incidence rates under the assumption of a shared coefficient of variation  
13 across groups. These are conservative estimates, since they do not account for the paired nature  
14 of the data<sup>58</sup>. Using pre-intervention neighbourhood incidence rates<sup>42</sup>, we created a power plot of  
15 the minimal detectable effect based on number of neighbourhoods affected by trail expansion.  
16 Outcome-specific incidence rates were calculated from MCHP-led Health Atlases<sup>42,59</sup> for 26  
17 well-defined Winnipeg neighbourhoods between 2002-2007 (pre-intervention, crude rates per  
18 100 person-years). Assuming an  $\alpha = 0.05$ ,  $\beta = 0.2$ , and an average neighbourhood  
19 incidence rate for the composite outcome  $\approx 4.95 \pm 0.45$  per 100 person years in treatment and  
20 comparison tracts<sup>42</sup>, we are powered to detect a 10% difference in the primary outcome with 50  
21 treatment neighbourhoods and 9% with 60 neighbourhoods<sup>58</sup>. This effect size is relevant to  
22 stakeholders as it translates into 350 fewer CVD-related events annually within the city. The  
23 effect is conservative, as previous population interventions like smoking bans (17% reduction in  
24 CVD events<sup>60</sup>), new public transportation (80% difference in odds of obesity<sup>61</sup>) or more walkable  
25 neighbourhoods (19% reduced incidence of type 2 diabetes<sup>21</sup>) have yielded larger effects.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

## 40 **Proposed analyses**

41  
42 To test the primary study hypothesis, that an expansion of an urban trail network will  
43 reduce population-level CVD-related mortality and morbidity in neighbourhoods within 400m-  
44 1200m of a new trail (intervention group), to a greater extent than neighbourhoods outside those  
45 boundaries, outcome data will initially be aggregated by neighbourhood and trends analyzed for  
46 the entire study period. The two primary outcome measures, composite end-points of incident  
47 major adverse CVD-related events and CVD-related risk factors will be treated as binary  
48 outcomes collected  $\sim 36$  during the pre-intervention period and at 36 time points after the  
49 intervention (i.e. trail expansion), following Cochrane recommendations<sup>35</sup>. There will be a  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 two-year<sup>35</sup> lag incorporated into the time series reflecting the time during which the trails were  
4 being constructed. These time points reflect extensive literature showing that CVD-related  
5 behaviours<sup>62,63</sup> and endpoints vary seasonally<sup>64,65</sup> and that the impact of natural experiments  
6 requires several years to be detected at the population level<sup>28,35,37</sup>.  
7  
8  
9

### 10 11 *Time Series Analyses*

12  
13  
14 We will use two different time series methods to estimate the effect of the intervention on  
15 CVD-related end-point incident rates in treatment neighbourhoods relative to trends among the  
16 comparison neighbourhoods. First, a multi-group segmented regression of interrupted time series  
17 data will be used to assess the effect of the intervention on CVD-related incidence, both  
18 immediately (change in level) and over time (change in trend) by creating indicator variables as  
19 described elsewhere<sup>37,40</sup>. The level will be the base rate of CVD-related end-points at the  
20 beginning of the pre-intervention period (2000) and the value immediately following each  
21 change point at which successive segments join until 2010. The trend is the rate of change of  
22 CVD-related end-points (in other words, the slope) during a segment. Autoregressive errors will  
23 be modeled to account for correlated outcomes.  
24  
25  
26  
27  
28  
29  
30

### 31 32 *Autoregressive integrated moving average*

33  
34  
35 An autoregressive integrated moving average (ARIMA) model will be fitted for the CVD  
36 incidence time series by using the standard approach for identification, estimation, and  
37 checking<sup>66</sup>. Trend and periodic seasonal terms will be applied to the entire study period (January  
38 2000 to July 2019). A separate ARIMA model will also be built for the pre-intervention period to  
39 forecast CVD evolution of the treated neighbourhoods. The number of CVD end-points  
40 prevented by the intervention will be estimated by calculating the difference between the  
41 predicted number and the observed number of cases. Should we encounter difficulty fitting an  
42 ARIMA model to a relatively small dataset, we will rely on exponential smoothing models or the  
43 Holt Winters Algorithm<sup>66</sup>. Although they require larger sample sizes, these methods are ideal for  
44 this project as (1) they permit a variety of different types of intervention effects to be modeled  
45 explicitly, and (2) they are well suited to forecasting future trends.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

### *Cost-Benefit analysis*

The cost-benefit analysis will focus on describing the “value for money” of the intervention. The objective of the economic analysis is to compare the cost and effect of the treatment group relative to the comparison group data collected in the study<sup>67</sup>. To align with the effectiveness analysis, the primary outcome variable in the economic analysis will be a composite endpoint of incident composite CVD-related end-points, similar to previous studies by one of the team members<sup>67-69</sup>. Costs for each participant will include those associated with the intervention (e.g., trail construction and maintenance costs) and health service utilization obtained from administrative data. From the perspective of the public payers (provincial and federal governments), we will conduct the economic analysis using the net benefit regression framework<sup>70,71</sup> which enables an adjustment for potential confounders. The main output of the economic analysis is the incremental net benefit of the treatment relative to the comparison group. In addition, we will estimate incremental cost-effectiveness ratios which will represent an incremental cost per one incident CVD end-point prevented or one CVD-related co-morbidity prevented. Furthermore, as there are more than one public payer for this intervention (e.g., Government of Winnipeg, Government of Manitoba), we will conduct separate analyses for each relevant perspective to assess the “value for money” specifically to each payer. We will characterize the uncertainty of our findings using a cost-effectiveness acceptability curve and 95% confidence interval. In addition, we will explore the possibility of building a decision analytic model which will examine the potential long-term economic impact of the intervention after the study period<sup>72</sup>. This economic model will use various data sources to estimate costs including the study<sup>73,74</sup>, published literature<sup>67-69</sup>, and expert opinion.

**Ethical Approval:** All aspects of the study design have been approved by the Biomedical Research Ethics Board at the University of Manitoba (Approval ID: REB\_HS20928 (H2017232)) and the Health Information Privacy Committee within the Province of Manitoba (Approval ID: HIPC - 2019/2020-05)

### **Discussion**



1  
2  
3 The proposed natural experimental study will fill a large gap in our understanding of the impacts  
4 of changes to the built environment on CVD-related outcomes. Specifically, we will provide  
5 critical experimental evidence for the impact of changes to urban spaces for recreational physical  
6 activity and active transportation on CVD-related morbidity and mortality. Additionally, to  
7 support evidence for future policies relating to urban activity corridors, we will also provide an  
8 estimate for the cost-effectiveness of large urban trail networks within cities.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

For peer review only

## DECLARATIONS

**Ethics approval and consent to participate:** This study was approved by the Biomedical Research Ethics Board at the University of Manitoba (H2017:232) and the Health Information Privacy Committee at the Winnipeg Regional Health Authority (HIPC - 2019/2020-05).

**Competing Interests:** The authors declare that they have no competing interests.

**Funding:** Funding for this project was provided by an operating grant from the Heart and Stroke Foundation of Canada (G-17-0018638) and the Canadian Institutes of Health Research (PJT-153449; CPP-137910). Funding bodies were not involved in the study design, conduct, interpretation or manuscript preparation for this project.

**Author Contributions:** All authors contributed to the study and manuscript in alignment with current ICMJE guidelines.

## References

1. Sallis JF, Bull F, Guthold R, et al. Progress in physical activity over the Olympic quadrennium. *Lancet* 2016.
2. Sallis JF, Floyd MF, Rodriguez DA, Saelens BE. Role of built environments in physical activity, obesity, and cardiovascular disease. *Circulation* 2012;125:729-37.
3. Meijer M, Rohl J, Bloomfield K, Grittner U. Do neighborhoods affect individual mortality? A systematic review and meta-analysis of multilevel studies. *Soc Sci Med* 2012;74:1204-12.
4. Frank LD, Kavage, S., Devlin, A. Health and the Built Environment: A Review 2012.
5. McCormack GR, Shiell A. In search of causality: a systematic review of the relationship between the built environment and physical activity among adults. *Int J Behav Nutr Phys Act* 2011;8:125.
6. Ferdinand AO, Sen B, Rahrkar S, Engler S, Menachemi N. The relationship between built environments and physical activity: a systematic review. *Am J Public Health* 2012;102:e7-e13.
7. Medicine Io. Bringing Public Health into Urban Revitalization: Workshop Summary. Bringing Public Health into Urban Revitalization: Workshop Summary. Washington (DC)2015.
8. Gascon M, Vrijheid M, Nieuwenhuijsen MJ. The Built Environment and Child Health: An Overview of Current Evidence. *Curr Environ Health Rep* 2016;3:250-7.
9. Mayne SL, Auchincloss AH, Michael YL. Impact of policy and built environment changes on obesity-related outcomes: a systematic review of naturally occurring experiments. *Obes Rev* 2015;16:362-75.
10. Sallis JF, Cerin E, Conway TL, et al. Physical activity in relation to urban environments in 14 cities worldwide: a cross-sectional study. *Lancet* 2016;387:2207-17.
11. Floyd MF, Spengler JO, Maddock JE, Gobster PH, Suau LJ. Park-based physical activity in diverse communities of two U.S. cities. An observational study. *Am J Prev Med* 2008;34:299-305.
12. Li F, Harmer P, Cardinal BJ, Bosworth M, Johnson-Shelton D. Obesity and the built environment: does the density of neighborhood fast-food outlets matter? *Am J Health Promot* 2009;23:203-9.
13. Polsky JY, Moineddin R, Glazier RH, Dunn JR, Booth GL. Relative and absolute availability of fast-food restaurants in relation to the development of diabetes: A population-based cohort study. *Can J Public Health* 2016;107:5312.
14. Beale SJ, Bending MW, Trueman P, Naidoo B. Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal. *Eur J Public Health* 2012;22:869-73.
15. Guo JY, Gandavarapu S. An economic evaluation of health-promotive built environment changes. *Prev Med* 2010;50 Suppl 1:S44-9.
16. Ding D, Gebel K. Built environment, physical activity, and obesity: what have we learned from reviewing the literature? *Health Place* 2012;18:100-5.
17. Abadie A, Diamond, A., Hainmueller, J. Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California's Tobacco Control Program. *Journal of the American Statistical Association* 2010;105:493-505.
18. Amatya A, Bhaumik D, Gibbons RD. Sample size determination for clustered count data. *Stat Med* 2013;32:4162-79.
19. Bancroft C, Joshi S, Rundle A, et al. Association of proximity and density of parks and objectively measured physical activity in the United States: A systematic review. *Soc Sci Med* 2015;138:22-30.
20. Clark S, Bungum T, Shan G, Meacham M, Coker L. The effect of a trail use intervention on urban trail use in Southern Nevada. *Prev Med* 2014;67 Suppl 1:S17-20.
21. Creatore MI, Glazier RH, Moineddin R, et al. Association of Neighborhood Walkability With Change in Overweight, Obesity, and Diabetes. *JAMA* 2016;315:2211-20.

22. Finlayson GS, Lix LM, Roos LL. The Whole Is Greater Than the Sum of the Parts: Using Data Linkage and Cohort Designs to Create Data Synergy at MCHP. *Health Policy* 2011;6:83-5.
23. Fransoo RR, Martens PJ, Need to Know T, et al. The rising prevalence of asthma: true increase, diagnostic exchange or diagnostic accuracy? *Health Policy* 2013;8:27-34.
24. Martens PJ. Straw into Gold: Lessons Learned (and Still Being Learned) at the Manitoba Centre for Health Policy. *Health Policy* 2011;6:44-54.
25. Nickel NC, Chateau DG, Martens PJ, et al. Data resource profile: Pathways to Health and Social Equity for Children (PATHS Equity for Children). *Int J Epidemiol* 2014;43:1438-49.
26. Roos LL, Soodeen RA, Bond R, Burchill C. Working more productively: tools for administrative data. *Health Serv Res* 2003;38:1339-57.
27. Smith M, Roos LL, Burchill C. Expanding the data repository: new technology and resources for the 21st century. *Health Policy* 2011;6:104-6.
28. Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis. *BMJ* 2015;350:h2750.
29. Sims M, Maxwell R, Bauld L, Gilmore A. Short term impact of smoke-free legislation in England: retrospective analysis of hospital admissions for myocardial infarction. *BMJ* 2010;340:c2161.
30. Jandoc R, Burden AM, Mamdani M, Levesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. *J Clin Epidemiol* 2015;68:950-6.
31. Clancy L, Goodman P, Sinclair H, Dockery DW. Effect of air-pollution control on death rates in Dublin, Ireland: an intervention study. *Lancet* 2002;360:1210-4.
32. Law MR, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. *Arch Intern Med* 2009;169:1969-74.
33. McAlister FA, Bakal JA, Majumdar SR, et al. Safely and effectively reducing inpatient length of stay: a controlled study of the General Internal Medicine Care Transformation Initiative. *BMJ Qual Saf* 2014;23:446-56.
34. Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. *BMJ* 2011;342:d108.
35. EPOC-Cochrane. EPOC- Criteria for including interrupted time series analyses. <http://epoccochrane.org/sites/epoccochrane.org/files/uploads/inttimepdf> 1998.
36. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. *Int J Technol Assess Health Care* 2003;19:613-23.
37. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. *J Clin Pharm Ther* 2002;27:299-309.
38. von Hippel P, Benson R. Obesity and the natural environment across US counties. *Am J Public Health* 2014;104:1287-93.
39. (EPOC). EPaOoC. Interrupted time series (ITS) analyses. Available at: <http://epoc.cochrane.org/epoc-specific-resources-review-authors> Oslo: Norwegian Knowledge Centre for the Health Services 2013.
40. Linden A, Adams JL. Applying a propensity score-based weighting model to interrupted time series data: improving causal inference in programme evaluation. *J Eval Clin Pract* 2011;17:1231-8.
41. Distasio J, Kaufman, A. The Divided Priarie City: Income Inequality among Winnipeg's Neighbourhoods: Institute for Urban Studies, University of Winnipeg; 2015.
42. Fransoo R, Martens, P., Prior H., Burchill, C., Koseva, I., Bailly A. The 2013 RHA Health Indicators Atlas. [http://mchp-appserv.cpe.umanitoba.ca/reference/RHA\\_2013\\_web\\_version.pdf](http://mchp-appserv.cpe.umanitoba.ca/reference/RHA_2013_web_version.pdf): University of Manitoba; 2013.

43. Lix LM, Yogendran MS, Shaw SY, Burchill C, Metge C, Bond R. Population-based data sources for chronic disease surveillance. *Chronic Dis Can* 2008;29:31-8.
44. Marrie RA, Fisk J, Tremlett H, et al. Differing trends in the incidence of vascular comorbidity in MS and the general population. *Neurol Clin Pract* 2016;6:120-8.
45. Ermagun AL, G.; Loh, T.H. . Urban Trails and Demand Response to Weather Variations. *Transp Res Part D Transp Environ* 2018;63:404-20.
46. Lix LM, Kuwornu JP, Kroeker K, et al. Estimating the completeness of physician billing claims for diabetes case ascertainment using population-based prescription drug data. *Health Promot Chronic Dis Prev Can* 2016;36:54-60.
47. Lindsey G PM, Hankey S. The Minnesota Bicycle and Pedestrian Counting Initiative: Implementation Study. In: Management MDoT-OoTS, ed. St. Paul, Minnesota: University of Minnesota; 2015.
48. Budowski A. Developing Expansion Factors to Estimate Cyclist Seasonal Average Daily Traffic in Winnipeg, MB. Winnipeg, Manitoba: University of Manitoba; 2015.
49. Chateau D, Metge C, Prior H, Soodeen RA. Learning from the census: the Socio-economic Factor Index (SEFI) and health outcomes in Manitoba. *Can J Public Health* 2012;103:S23-7.
50. Lees L, Slater T, Wyly E. The Birth of Gentrification. *Gentrification*. New York, NY: Taylor and Francis Group, LLC; 2013:3-38.
51. Kavanagh A, Bentley RJ, Turrell G, Shaw J, Dunstan D, Subramanian SV. Socioeconomic position, gender, health behaviours and biomarkers of cardiovascular disease and diabetes. *Soc Sci Med* 2010;71:1150-60.
52. Mackenbach JP, Cavelaars AE, Kunst AE, Groenhouf F. Socioeconomic inequalities in cardiovascular disease mortality; an international study. *Eur Heart J* 2000;21:1141-51.
53. Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. *Am J Public Health* 1992;82:816-20.
54. Lysy Z, Booth GL, Shah BR, Austin PC, Luo J, Lipscombe LL. The impact of income on the incidence of diabetes: a population-based study. *Diabetes Res Clin Pract* 2013;99:372-9.
55. Lipscombe LL, Austin PC, Manuel DG, Shah BR, Hux JE, Booth GL. Income-related differences in mortality among people with diabetes mellitus. *CMAJ* 2010;182:E1-E17.
56. Brook JR, Setton EM, Seed E, Shooshtari M, Doiron D, Consortium CTCUEHR. The Canadian Urban Environmental Health Research Consortium - a protocol for building a national environmental exposure data platform for integrated analyses of urban form and health. *BMC Public Health* 2018;18:114.
57. Pattanayak CW, Rubin DB, Zell ER. [Propensity score methods for creating covariate balance in observational studies]. *Rev Esp Cardiol* 2011;64:897-903.
58. Donner A, Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. London, ON: Arnold; 2000.
59. Fransoo R, Martens, P., Burland, E., Prior H., Burchill, C. *The Need to Know Team*. Manitoba RHA Indicators Atlas 2009. Elnnipeg, MB: University of Manitoba; 2009.
60. Pell JP, Haw S, Cobbe S, et al. Smoke-free legislation and hospitalizations for acute coronary syndrome. *N Engl J Med* 2008;359:482-91.
61. MacDonald JM, Stokes RJ, Cohen DA, Kofner A, Ridgeway GK. The effect of light rail transit on body mass index and physical activity. *Am J Prev Med* 2010;39:105-12.
62. Schaefer L, Plotnikoff RC, Majumdar SR, et al. Outdoor time is associated with physical activity, sedentary time, and cardiorespiratory fitness in youth. *J Pediatr* 2014;165:516-21.
63. Shephard RJ, Aoyagi Y. Seasonal variations in physical activity and implications for human health. *Eur J Appl Physiol* 2009;107:251-71.

- 1  
2  
3 64. Danet S, Richard F, Montaye M, et al. Unhealthy effects of atmospheric temperature and pressure  
4 on the occurrence of myocardial infarction and coronary deaths. A 10-year survey: the Lille-World Health  
5 Organization MONICA project (Monitoring trends and determinants in cardiovascular disease). *Circulation*  
6 1999;100:E1-7.  
7  
8 65. Group TE. Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular  
9 disease, respiratory disease, and all causes in warm and cold regions of Europe. The Eurowinter Group.  
10 *Lancet* 1997;349:1341-6.  
11 66. Brockwell PJ. DR. Introduction to time series and forecasting. 2nd ed. New York, NY: Springer;  
12 2001.  
13 67. Tricco AC, Cogo E, Isaranuwatthai W, et al. A systematic review of cost-effectiveness analyses of  
14 complex wound interventions reveals optimal treatments for specific wound types. *BMC Med* 2015;13:90.  
15 68. Marsh JD, Birmingham TB, Giffin JR, et al. Cost-effectiveness analysis of arthroscopic surgery  
16 compared with non-operative management for osteoarthritis of the knee. *BMJ Open* 2016;6:e009949.  
17 69. Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting  
18 versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-  
19 analysis. *BMJ* 2014;349:g5459.  
20 70. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something  
21 blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. *Health Econ*  
22 2002;11:415-30.  
23 71. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup  
24 analysis for non-censored cost-effectiveness data. *Health Econ* 2004;13:461-75.  
25 72. Drummond MF, Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. Methods for the  
26 economic evaluation of health care programmes. Oxford, UK: Oxford university press.; 2015.  
27 73. Cui Y, Doupe M, Katz A, Nyhof P, Forget EL. Economic evaluation of Manitoba Health Lines in the  
28 management of congestive heart failure. *Healthc Policy* 2013;9:36-50.  
29 74. Forget EL. New questions, new data, old interventions: the health effects of a guaranteed annual  
30 income. *Prev Med* 2013;57:925-8.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tables and Figures

Figure 1. Map of Trail Locations within Winnipeg, Manitoba Canada.

Table 1. Details of the intervention: New Urban Trails

Table 2: Outcome Measures

Table 3: Potential sources of confounding between intervention and control arms that are available within linked databases.

For peer review only

Table 1. Details of the intervention: New Urban Trail Greenways

Variable	Northeast Pioneers	Yellow Ribbon	Bishop Grandin	Transcona Trail
Original Land Use	Converted rail line	Paved grassland	Paved grassland	Paved grassland / industrial re-appropriation
Const. Start Date	Summer '07	Summer '09	Summer '08	Summer '10
Completion date	~Autumn '12	~Autumn '11	~Autumn '10	~Autumn '10
Const. Start Date	Summer '07	Summer '09	Summer '08	Summer '10
Completion date	~Autumn '12	~Autumn '11	~Autumn '10	~Autumn '10
Distance of Trail	6.5km	5km	8km	6.7 km
Dissemination areas within 800m access	103	48	243	45
Estimated pop. within 800m	53 308	20 376	153 015	21 915
Immediate adjacent environment	Trail located between two major roadways	Greenspace, neighbourhood, airport	Major roadway and neighbourhoods/business parks	Neighbourhood, grassland, business park
Mixed land use	High (homes, schools, shopping, recreation, parks)	Medium (homes, schools, parks)	High (homes, schools, shopping, parks)	Medium (homes, shopping, parks)



Table 2. Outcome Measures in the natural experiment of urban trail expansion

Category	Variable	Outcome	Definition	Source		
Primary	Major adverse cardiovascular events (MACE) - Composite	CVD-related mortality	Death in vital statistics mortality data with most responsible cause of death coded as CHF, IHD or stroke.	Vital statistics mortality		
		Ischemic heart disease	-1+ Inpatient Hospitalizations -2+ Physician visits in 5 years -1 Physician Visit & 2+ Rx in 5 years	Hospital abstracts, Medical claims, DPIN prescription dispensations		
		Congestive heart failure	-1+ inpatient visits or 2+ physician visits	Hospital abstracts, Medical claims		
		Cerebrovascular event	- 1+ Inpatient Hospitalizations - death in hospital	Hospital abstracts		
		Secondary	CVD-related risk factors - Composite	Hypertension	-1+ Inpatient Hospitalizations -2+ Physician visits in 2 years	Hospital abstracts, Medical claims
				Diabetes	-1+ Inpatient Hospitalizations -2+ Physician visits in 3 years -2+ Rx for glucose lowering agents in 3 years,	Hospital abstracts, Medical claims, Prescription dispensations
Dyslipidemia	-1+ Hospitalization -2+ Physician visits in 3 years -2+ Rx for statins in 3 years			Hospital abstracts, Medical claims, Prescription dispensations		
Secondary	Trail use	Bicycle counts		Eco-Counter Magnetic Zelts		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

located beneath  
greenways

Exploratory	Income	Household	Self-reported	Intercept surveys
	Ethnicity		Self-reported	
	Gender	Male, female, other	Self-reported	
	Residence	Postal code	Self-reported	
	Weekly use	Visits/week	Self-reported	
	Time on trail	Minutes/use	Self-reported	

---

CHF = congestive heart failure; CVD = cardiovascular disease; ICD = international classification code; IHD = ischemic heart disease, Rx = prescription


For peer review only

Table 3. Potential sources of confounding between intervention and control groups that are available within linked databases

Category	Variable	Definition	Source	Years available
Socio-economic status	Income	Household income	Census	2006 and 2016
	SEFI	Material and social deprivation	MCHP repository	Annual
Demographics	Age		Census	2006 and 2016
	Sex		Census	2006 and 2016
	Ethnicity		Census	2006 and 2016
	Immigration status		Census	2006 and 2016
Gentrification	Change in mean age neighbourhood	Taxation valuation of value of property	City of Winnipeg	2008 to 2018
	Property value			
Built environmental factors that support physical activity	Greenspace	Distance to park (kms)	DMTI/CANUE	2006 and 2016
	Walkability	Population density, mixed land use, connectivity	CAN-ALE (CANUE)	2006 and 2016
	Fitness/Recreation Centres	Distance to centre	CANUE	2006 and 2016

SEFI = socioeconomic factor index; DMTI = Digital Mapping company name; MCHP = Manitoba Centre for Health Policy; kms = kilometers

Figure 1. Trails included in the natural experiment as of 2016



Complete trail map includes old and new trails, comprising ~400km of total trails. Large red trails are “high dose” multi-use trails that extend across multiple neighbourhoods and accessible 12 months of the year

(A= Northeast pioneers greenway; B= Yellow ribbon greenway; C= Harte Trail & D= Bishop Grandin green way). Other green lines represent medium or low impact bike trails or gravel trails not used in winter or only for active commuting. Note large red areas that have not received trails.

Appendix sTable 1. Diseases or risk factors classification and corresponding International Classification of Disease (ICD) codes, in alphabetical order.

INDICATION	ICD TITLE	ICD 10 CODE	ICD 9 CODE
<b>Diagnoses indicative of a cardiovascular disease endpoint – Primary outcome</b>			
Ischemic heart disease	Angina pectoris	I20	413
	Acute myocardial infarction	I21	410, 434.91
	Subsequent myocardial infarction	I22	412
	Other acute ischaemic heart diseases	I24	411
	Chronic ischaemic heart disease	I25	414
Cardiac arrest	Cardiac arrest	I46	427.5
Heart failure	Heart failure	I50	428
Cerebral infarction	Cerebral infarction	I63	433, 434, 435
	Stroke	I64	437.0, 437.1, 437.3
<b>Diagnoses indicative of a cardiovascular disease risk factor – Secondary Outcome</b>			
Diabetes	Diabetes	E11	250
Hyperlipidemia	Dyslipidemia	E78	272.3, 272.5, 272.6
Hyperlipidemia	Pure hypercholesterolaemia	E78.0	272.0
	Pure hyperglyceridaemia	E78.1	272.1
	Mixed hyperlipidaemia	E78.2	272.2
	Hyperlipidaemia, unspecified	E78.5	272.4
Hypertension	Essential (primary) hypertension	I10	401, 459.3
	Hypertensive heart disease	I11	402

	Hypertensive renal disease	I12	403
	Hypertensive heart and renal disease	I13	404
<b>Diagnoses leading to exclusion from the cohort</b>			
Cardiomyopathy	Endocardial fibroelastosis	I42.4	425.3
	Endomyocardial disease	I42.3	425.0
	Congenital cardiomyopathy	I42.8	Not applicable
	Familial cardiomyopathy	I42.9	425.9
Congenital malformation of circulatory system	Congenital malformations of the circulatory system	Q20 to Q28	745, 746, 747, 759.9
Cystic fibrosis	Cystic fibrosis	E84	277.0
<b>Ineligible diagnoses (not considered as outcome, but did not warrant exclusion of the participant)</b>			
Other cardiovascular problems (eg cause is viral, genetic, alcoholic, etc.)	Other cardiovascular problems	E78.7, E78.8	424.9, 425.2, 425.5, 425.7, 425.8, 425.9
Arrhythmia*	Cardiac dysrhythmias	I49	427 excluding 427.5 (see Cardiac arrest)
	Abnormalities of heart beat	R00 to R03	785.3

\*Arrhythmias were ineligible because their definition in administrative databases has not yet been validated and a local pediatric cardiologist informed us that most dysrhythmia diagnoses or referrals would not be considered cardiovascular disease or risk.

# BMJ Open

## Physical Activity Trails in an Urban Setting and Cardiovascular Disease Morbidity and Mortality in Winnipeg, Manitoba, Canada: A Study Protocol for a Natural Experiment

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036602.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Jan-2020
Complete List of Authors:	Hobin, Erin; Dalla Lana School of Public Health, University of Toronto, Swanson, Anders; Winnipeg Trails Booth, Gillian; University of Toronto, Endocrinology and Metabolism Russell, Kelly; University of Manitoba, Pediatrics and Child Health Rosella, Laura; University of Toronto, Dalla Lana School of Public Health Smith, Brendan; University of Toronto, Dalla Lana School of Public Health Manley, Ed; University College London, The Bartlett Centre for Advanced Spatial Analysis (CASA) Isaranuwatthai, Wanrudee; University of Toronto Institute of Health Policy Management and Evaluation Whitehouse, Stephanie; City of Winnipeg, Active Transportation Brunton, Nicole; University of Manitoba Faculty of Health Sciences, Pediatrics and Child Health McGavock, Jonathan; University of Manitoba, Pediatrics
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Sports and exercise medicine, Cardiovascular medicine, Diabetes and endocrinology
Keywords:	Ischaemic heart disease < CARDIOLOGY, EPIDEMIOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, SPORTS MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



Physical Activity Trails in an Urban Setting and Cardiovascular Disease Morbidity and Mortality  
in Winnipeg, Manitoba, Canada: A Study Protocol for a Natural Experiment

Erin Hobin, PhD<sup>1</sup>, Anders Swanson<sup>2</sup>, Gillian L. Booth MD, MSc<sup>3</sup>, Kelly Russell PhD<sup>4,5</sup>, Laura  
Rosella PhD, MHSc<sup>6</sup>, Brendan Smith<sup>1</sup>, Ed Manley PhD<sup>7</sup>, Wanrudee Isaranuwatthai PhD<sup>3</sup>,  
Stephanie Whitehouse<sup>4,5,8</sup>, Nicole Brunton, MSc<sup>4,5,8</sup>, Jonathan McGavock\*, PhD<sup>4,5,8</sup>

(1) Public Health Ontario (2) Winnipeg Trails Association; (3) MAP Centre for Urban Health  
Solutions, St. Michaels Hospital (4) Department of Pediatrics and Child Health, Max Rady Faculty  
of Health Sciences, University of Manitoba, (5) Children's Hospital Research Institute of  
Manitoba (6) Dalla Lana School of Public Health, University of Toronto. (7) The Bartlett Centre  
for Advanced Spatial Analysis, Faculty of the Built Environment, University College London (8)  
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Research Theme at the  
Children's Hospital Research Institute of Manitoba.

\*Corresponding Author

Jonathan McGavock, PhD

Associate Professor,

Department of Pediatrics and Child Health

Faculty of Health Sciences, University of Manitoba

511 JBRC. Children's Hospital Research Institute of Manitoba

715 McDermot Ave. Winnipeg, MB R3E 3P4

Phone: 1-204-480-1359

Email: [jmcgavock@chrim.ca](mailto:jmcgavock@chrim.ca)

Sources of Funding: Canadian Institutes of Health Research (PJT-153449; CPP-137910) and the  
Heart and Stroke Foundation of Canada (G-17-0018638)

Word Count: 3718

Figures: 1

Tables: 3

## Abstract

**Introduction:** Aspects of the built environment that support physical activity are associated with better population health outcomes. Few experimental data exist to support these observations. This protocol describes the study of the creation of urban trails on cardiovascular disease (CVD)-related morbidity and mortality in a large urban centre.

**Methods and Analysis:** Between 2008 and 2010, the city of Winnipeg Canada, built four, paved, multi-use (eg. cycling, walking, running), two-lane trails, that are 5-8km long and span ~60 neighbourhoods. Linking a population-based health data with census and environmental data, we will perform an interrupted time series analysis to assess the impact of this natural experiment on CVD-related morbidity and mortality among individuals 30-65 years of age residing within 400m-1200m of the trail. The primary outcome of interest is a composite measure of incident major adverse CVD events (i.e. CVD-related mortality, ischemic heart disease, stroke, congestive heart failure). The secondary outcome of interest is a composite measure of incident CVD-related risk factors (i.e. diabetes, hypertension, dyslipidemia). Outcomes will be assessed quarterly in the 10 years before the intervention and five years following the intervention, with a four year interruption. We will adjust analyses for differences in age, sex, ethnicity, immigration status, income, gentrification and other aspects of the built environment (i.e. greenspace, fitness/recreation centres, walkability). We will also assess trail use and trail user profiles using field data collection methods (Trial Registration: NCT04057417).

**Ethics and Dissemination:** Ethical approvals for the study have been granted by the Health Research Ethics Board at the University of Manitoba and the Health Information Privacy Committee within the Winnipeg Regional Health Authority. We have adopted an integrated knowledge translation approach. Information will be disseminated with public and government partners.

### Strengths and Limitations:

- We are relying on natural experiment consisting of the expansion of trails within an urban environment to test our research hypothesis.
- We have access to data for the entire urban population over a 20-year time frame, capturing all health-related end-points
- We are triangulating health outcome data with robust field data on trail use to describe the population impact of the trail expansion
- We cannot determine individual-level physical activity levels in persons living within intervention neighbourhoods
- We will not be able to capture individual-level trail use and therefore do not know what percentage of the population within each neighbourhood are using the trails

### Rationale

The built environment is at the interface of public and health policy<sup>1,2</sup>. Social scientists have explored the association between the environment and health for decades<sup>3</sup>, and a growing body of evidence show some aspects of the built environment are associated with cardiovascular disease (CVD)<sup>3</sup> and its preceding risk factors<sup>4-8</sup>. The favourable associations between aspects of the built environment and CVD-related health have been observed primarily through the promotion of physical activity.

Various elements of the built environment are associated with increased physical activity, particularly access to walkable neighbourhoods and green space, and the proximity of recreation facilities<sup>2,4</sup>. Importantly, individuals living in built environments that facilitate physical activity (e.g. greater access to walkable neighbourhoods and green space) display more favourable cardiovascular health profiles<sup>2,9,10</sup>. For example, individuals are 10-20% more likely to meet daily recommendations for physical activity and 5% less likely to have obesity for every incremental increase in access to recreational facilities, green space, and walkable neighbourhoods<sup>2,11</sup>. Conversely, individuals living in environments with more fast food outlets and fewer healthy food options are more likely to eat unhealthy food, and live with obesity or diabetes<sup>12,13</sup>. Based on these associations, changes to the built environment are projected to be a cost-effective population health intervention to promote physical activity and prevent CVD<sup>14,15</sup>. Unfortunately, there are limited studies of the built environment and CVD-related morbidity and mortality. Additionally, current evidence in this field largely draws on underpowered cross-sectional studies<sup>4,16</sup>. While associations between the built environment and health behaviours

1  
2  
3 seem robust, it remains unclear if changes to the built environment are associated with improved  
4 health outcomes. Accordingly, experimental data are needed to determine if, and the extent to  
5 which, changes to the built environment are associated with reduced CVD-related morbidity and  
6 mortality<sup>17-19</sup>.  
7  
8  
9

10  
11 Elements of the built environment that support physical activity include neighbourhood  
12 walkability, access to greenspace and proximity to fitness/recreation centres<sup>2</sup>. Urban multi-use  
13 trails are an additional, but poorly studied, aspect of the built environment that could support  
14 greater population-level daily physical activity<sup>20</sup>. Urban trails are multi-use protected areas for  
15 cycling alone or a combination of cycling, walking and running. They can be used to facilitate  
16 active transportation or a combination of active transport and recreational physical activity.  
17  
18 Despite widespread growth of trail networks in urban areas, they are not included in calculations  
19 of walkability within a neighbourhood<sup>21</sup>, and little information exists for their association with  
20 health outcomes.  
21  
22  
23  
24  
25  
26

27  
28 As randomized controlled trials are virtually impossible in this field, natural experiments  
29 provide the only feasible opportunity to generate experimental evidence to examine a potential  
30 causal link between the built environment and health outcomes. The most recent systematic  
31 review and meta-analysis investigating the influence of the built environment on health  
32 outcomes, found no experimental studies and none of the studies included disease-specific CVD  
33 or CVD-related outcome measures (i.e. mortality, myocardial infarction, and/or co-morbid  
34 conditions)<sup>9</sup>. Consistent with the results of observational studies examining associations between  
35 the built environment and health, the majority of natural experiments revealed improvements in  
36 more proximal measures of CVD, for example physical activity; however, there is no  
37 experimental evidence examining whether changes in the built environment lead to changes in  
38 CVD-related morbidity or mortality<sup>9</sup>.  
39  
40  
41  
42  
43  
44  
45  
46

47  
48 The current study describes the methods and protocol for a natural experimental study  
49 evaluating the impact of a large expansion of an urban trail network on CVD-related morbidity  
50 and mortality in a large urban centre in Canada.  
51  
52  
53  
54  
55  
56  
57

## Methods and Analysis

### *Study Aims and Hypotheses*

The primary objective of this natural experimental study is to capitalize on major changes to the built environment that occurred in Winnipeg, Canada between 2010 and 2014 to determine if a significant expansion of an urban trail network is associated with reduced CVD-related morbidity and mortality. The secondary aim of the study is to determine the cost-benefit ratio of this intervention compared to forecasted costs associated without the expansion of the urban trail network. The last aim of the study is to describe patterns of trail use and trail users during the intervention time period. Our primary study hypothesis is that an expansion of an urban trail network will reduce population-level CVD-related mortality and morbidity in neighbourhoods within 400-1200m of the new trail compared to neighbourhoods lying outside these boundaries.

### *Study Design*

The most robust approach to test this research hypothesis is a quasi-experimental interrupted time series analysis with a comparison condition. The proposed interrupted time series analysis is strengthened by the use of a social and health data repository that provides an opportunity to link census, social and health data for the entire population of the City of Winnipeg beginning in 1995<sup>22-27</sup>. Interrupted time series designs are considered the most valid quasi-experimental designs when a randomized controlled trial is not possible<sup>28,29</sup>. They are the preferred design for population health interventions or pragmatic experiments as they strengthen pre-post designs, particularly if an appropriate comparison condition is available<sup>28-30</sup>. This approach is considered the gold standard for a natural experiment, as it captures real-world changes in population-level health outcomes following large policy or practice changes<sup>31-34</sup> that can eventually inform changes in health systems.

Using population-level outcome data over a 20-year period (2000 – 2019), we will construct an interrupted time series with a comparison condition. We selected a 20-year time frame as it will provide ~60 data points (~40 before and ~20 after the intervention) to test for changes in the slopes of CVD-related morbidity and mortality between groups before and after the expansion of urban trails. This design will allow us to better control for biases that

1  
2  
3 accompany non-randomized study designs<sup>35-37</sup> such as (1) secular trends, which in this case may  
4 be changes in CVD rates that could be interpreted as intervention effects if comparison  
5 neighbourhoods were not available; (2) seasonal effects, as rates of CVD tend to be higher  
6 during winter months<sup>38</sup>; (3) duration of the intervention where trails may only be used in the first  
7 few months or years following construction and data collected in the year or two following the  
8 expansion would not have identified this effect; (4) random short-term fluctuations in CVD rates  
9 that may occur which do not reflect overall trends and can lead to biased intervention effect  
10 estimates if only a short time window is studied, and (5) autocorrelation where rates of CVD are  
11 likely to be associated between time points and between neighbourhoods. In addition to  
12 employing an interrupted time series design to minimize biases, we will employ a series of  
13 complimentary statistical features that include segmented time series regression techniques<sup>28,37</sup>  
14 and autoregressive integrated moving average models<sup>30,39</sup>. To improve comparability of  
15 treatment and comparison neighbourhoods, we will create balanced treatment and comparison  
16 groups using propensity score matching<sup>40</sup>.

### 27 28 *Study population*

29  
30  
31 This study will be conducted within the metropolitan area of Winnipeg, Manitoba,  
32 Canada's seventh largest urban centre. It is considered a slow growth city, relative to other major  
33 urban centres in Canada<sup>41</sup>. Winnipeg includes ~700,000 residents, representing >50% of the  
34 population of the province of Manitoba. Data from administrative health care databases within  
35 the Manitoba Centre for Health Policy (MCHP) will be used to derive population-level estimates  
36 of CVD and CVD-related co-morbid conditions as previously done<sup>42-44</sup>. Health information for  
37 local residents will be linked to dissemination-level data using individual postal codes. We will  
38 restrict the analyses to the adult population aged 30 to 65 years as previously done<sup>21</sup>, as CVD  
39 end-points are <1/10,000 among persons under 30 years in Manitoba<sup>42</sup>.

### 40 41 42 43 44 45 46 47 *Intervention group: Winnipeg urban trail network expansion*

48  
49  
50 In the Canadian context, an urban trail is a multi-use public path which creates an  
51 attractive transportation and leisure activity corridor through a built environment, used largely  
52 during the summer months<sup>45</sup>. Urban trails are an ideal component of the built environment to  
53 study with a quasi-experimental design and aggregated data. In contrast to more commonly  
54  
55  
56  
57

1  
2  
3 studied aspects of the built environment that promote physical activity (e.g. neighbourhood  
4 walkability, green space), trails are substantially easier to manipulate, as they require minimal  
5 space within the urban landscape and can affect a much larger segment of the urban population  
6 as they cross multiple neighbourhoods.  
7  
8  
9

10  
11 Between 2008 and 2010, the City of Winnipeg and Province of Manitoba invested \$25  
12 million to expand the infrastructure for leisure and transportation-based physical activity. Several  
13 mixed socio-economic neighbourhoods within Winnipeg were exposed to one of four new urban  
14 trails between 2008 and 2010, affecting roughly 250,000 residents within ~350 dissemination  
15 areas. Details of the greenways are provided in Table 1 and their location within the city are  
16 provided in Figure 1. The four multi-use urban trails are over five kilometers in length, paved,  
17 two lane paths that are cleared and maintained by the City of Winnipeg Department of  
18 Transportation 12 months of the year. They provide efficient and desirable trails for both active  
19 transportation and leisure physical activity. The majority of the population of Winnipeg do not  
20 live in dissemination areas that are within a reasonable distance to access the urban trails and  
21 therefore will be treated as the control condition. (Figure 1 – Map).  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 *Outcome measures*

32  
33  
34 The primary outcome measure will be a composite endpoint of incident CVD-related  
35 events including new hospital admissions for cardiac-related events (CVD-mortality, ischemic  
36 heart disease and stroke) and CVD-related co-morbidities (Table 2). ICD-9-CM codes will be  
37 used up to 1 April 2004 and ICD-10-CA codes afterwards for disease diagnosis (appendix, Table  
38 1). These end-points were selected as they represent the largest burden of CVD-related morbidity  
39 in Canada, are the most relevant to policy makers and most likely to be modified by increased  
40 physical activity levels. These outcomes are derived from validated algorithms, providing an  
41 extremely accurate and sensitive capture of end-points<sup>43,46</sup>. Heart failure and peripheral artery  
42 disease will not be included in the composite outcome as algorithms have yet to be validated in  
43 the repository. The secondary outcome measure will be CVD-related co-morbidities, including  
44 hypertension, diabetes and dyslipidemia, as they are more proximal outcomes associated with  
45 changes in physical activity levels<sup>1,2,21</sup> and therefore more likely to change within  
46 neighbourhoods during the relatively short time frame of this intervention (Table 2).  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

## Exploratory and Confounding Variables

### *Trail Usage*

Eco-Counter Dual Inductive Loop Zelts are automated cyclist counters that will be used to measure trail usage as an exploratory variable, between 2014 and 2019<sup>47</sup>. Zelts have been discussed as an acceptable and reliable research tool to capture trail use<sup>48</sup>. Zelts are comprised of a main unit and sensory wiring. The main unit includes a battery, Global System for Mobile (GSM) transmission device and counting unit buried in manholes on the outer edge of a trail. Zelt counters will be placed at ten locations across the five trail developments and will collect cyclist data for 24 hours/day, seven days per week. Data collected from Zelts are time stamped and automatically uploaded to Eco-Visio online software via cellular networks at 3:00 a.m. everyday.

### *Field data collection to survey trail users*

To determine trail user demographics, we will conduct two waves of intercept surveys among a convenience sample of ~1000 trail users, one wave in 2018 and one in 2019. Users will be asked to complete a brief survey to provide demographic information, self-reported trail usage and the perceived impact of usage on both their physical and mental health. These surveys will be designed to be completed in three to five minutes, to minimize participant burden and facilitate the collection of responses from the highest possible number of users. Demographic data will include self-identified gender and ethnicity, age group, residential postal code, newcomer status and annual household income. Analyses of these data will determine which, if any, specific groups experience disproportionate access to the trails. Usage data will outline typical weekly trail use (in terms of frequency, duration and types of activities), commute time to reach trail paths, and reasons for using the trail system. Survey collection will occur year-round when weather permits as either paper or technological survey instruments may not perform optimally in extreme winter conditions.

Survey participants will be asked to provide the first three digits of their postal code. This data will be used to geo-map the neighbourhoods of visiting users for each trail through dot density mapping techniques. Geo-maps will reflect the population distribution and demographic variation represented at each trail. Postal code data and produced geo-maps will also be



1  
2  
3 combined with City of Winnipeg Census data (2016) to provide insight into represented  
4 residential neighbourhood distributions for ethnicity and household income.  
5  
6

### 7 **Confounding Variables**

8  
9 A detailed list of confounding variables and their source are provided in Table 3.  
10

11  
12 *Socioeconomic status:* Household income will be determined by census data, which are  
13 publically available every five years. We will rely on data from the 2006 and 2016 surveys to  
14 assess household income. We will also rely on a validated continuous index of material and  
15 social deprivation (socio-economic factor index, SEFI), that is calculated for each dissemination  
16 area in the province of Manitoba and reflects neighbourhood-level socio-economic well being<sup>49</sup>.  
17  
18

### 19 *Gentrification*

20  
21  
22 Gentrification describes demographic changes that may occur in a community over time  
23 as individuals with a higher socioeconomic status move into lower socioeconomic areas<sup>50</sup>. Since  
24 socioeconomic status can have large implications for outcomes related to CVD<sup>51-53</sup>, diabetes<sup>51,54</sup>  
25 and mortality<sup>52,55</sup>, it will be important to account for gentrification within neighbourhoods. First,  
26 changes in property taxation between 2008 and 2018 assessed by the City of Winnipeg will be  
27 examined for each included neighbourhood to approximate increases or decreases in household  
28 value. Additionally, 2001 Canadian Census data and the 2016 National Household Survey data  
29 will be used to determine shifts in relevant indicators including poverty, education,  
30 unemployment rates, language barriers, average household income and ethnicity. Finally, data  
31 characterizing retail indicators will be obtained from DMTI Spatial Inc (2006 to 2016) to  
32 compare the number and ratio of specialty coffee houses versus coffee and doughnut shops per  
33 capita within neighbourhoods<sup>21</sup>. This will act as a surrogate variable representing demographic  
34 shifts in retail demands.  
35  
36

### 37 *Built Environment Determinants of Physical Activity*

38  
39  
40 The Canadian Urban Environmental Health Research Consortium (CANUE) is a multi-  
41 disciplinary collaboration of specialists focused on environmental exposures and population  
42 health.<sup>56</sup> CANUE integrates several population health databases and environmental exposure  
43 datasets into an openly available resource. From the CANUE dataset we will integrate examine  
44  
45  
46

1  
2  
3 several estimates of greenspace, including accessibility of green space, type of vegetation, tree  
4 canopy cover in control for access to greenspaces in the treatment and comparison and  
5 intervention neighbourhoods across Winnipeg via the 2016 ArcGIS survey. All these data will be  
6 treated as confounding and adjusted for in the final analyses. We will also assess neighbourhood  
7 walkability using CAN-ALE scores calculated from a GIS-based composite of population  
8 density, mixed land use, access to public transportation and street connectivity. Finally, we will  
9 estimate the number of fitness and recreation centres within three kilometres of each household.  
10  
11  
12  
13  
14  
15

16 **Patient and Public involvement:** Members of the public will be involved at several stages of  
17 the study. Members of the public were involved in developing the study design, in response to  
18 priorities established by a local organization (Winnipeg Trails Association) dedicated to  
19 supporting urban trails for physical activity. Members of the public will help with recruitment of  
20 trail users during field data collection and collect survey responses. This organization will also  
21 develop public and policy maker-friendly tools to disseminate results of the study via their social  
22 media platforms and at local meetings. The organization, represented by its executive director  
23 (AS), acted as a co-applicant on the grant and a collaborator throughout the project.  
24  
25  
26  
27  
28  
29  
30

### 31 **Power calculation and sample size**

32  
33  
34 We have the advantage of leveraging a health data repository that includes the majority of  
35 residents in Winnipeg and captures all endpoints that occurred within each time point for  
36 residents in that neighbourhood. During the pre-intervention period (2006/07 and 2011/12),  
37 overall mortality, annual incident rates of ischemic heart, hypertension, and diabetes were nearly  
38 identical between treatment and comparison neighbourhoods<sup>42</sup>. The stability of outcome  
39 measures will facilitate the detection of small, but meaningful, changes in trends or absolute  
40 events within treatment neighbourhoods. Segmented regression with propensity score matching  
41 will be used to compare changes in event rates between treatment and comparison  
42 neighbourhoods. The goal of the propensity score matching will be to pair the approximately 60  
43 treated units (i.e. neighbourhoods) with approximately 60 randomly selected comparison units  
44 balanced on key covariates known to influence physical activity levels and CVD-related  
45 mortality and morbidity, (socioeconomic status [SES], age, ethnicity and walkability) permitting  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 analysis of data as if it arose from a randomized design<sup>57</sup>. Power analysis is based on a  
4 comparison of incidence rates in matched treated and comparison units.  
5  
6

7  
8 Sample size calculations for clustered count data, where treatment assignment is at the  
9 neighbourhood level and the outcome is an incidence rate (e.g. Poisson count), were used to  
10 estimate the minimal detectable effect size<sup>18</sup>. We applied the Hayes-Donner method to estimate  
11 the number of neighbourhoods required to discern a given effect size, expressed as the difference  
12 between group-specific incidence rates under the assumption of a shared coefficient of variation  
13 across groups. These are conservative estimates, since they do not account for the paired nature  
14 of the data<sup>58</sup>. Using pre-intervention neighbourhood incidence rates<sup>42</sup>, we created a power plot of  
15 the minimal detectable effect based on number of neighbourhoods affected by trail expansion.  
16 Outcome-specific incidence rates were calculated from MCHP-led Health Atlases<sup>42,59</sup> for 26  
17 well-defined Winnipeg neighbourhoods between 2002-2007 (pre-intervention, crude rates per  
18 100 person-years). Assuming an  $\alpha = 0.05$ ,  $\beta = 0.2$ , and an average neighbourhood  
19 incidence rate for the composite outcome  $\approx 4.95 \pm 0.45$  per 100 person years in treatment and  
20 comparison tracts<sup>42</sup>, we are powered to detect a 10% difference in the primary outcome with 50  
21 treatment neighbourhoods and 9% with 60 neighbourhoods<sup>58</sup>. This effect size is relevant to  
22 stakeholders as it translates into 350 fewer CVD-related events annually within the city. The  
23 effect is conservative, as previous population interventions like smoking bans (17% reduction in  
24 CVD events<sup>60</sup>), new public transportation (80% difference in odds of obesity<sup>61</sup>) or more walkable  
25 neighbourhoods (19% reduced incidence of type 2 diabetes<sup>21</sup>) have yielded larger effects.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

## 40 **Proposed analyses**

41  
42 To test the primary study hypothesis, that an expansion of an urban trail network will  
43 reduce population-level CVD-related mortality and morbidity in neighbourhoods within 400m-  
44 1200m of a new trail (intervention group), to a greater extent than neighbourhoods outside those  
45 boundaries, outcome data will initially be aggregated by neighbourhood and trends analyzed for  
46 the entire study period. The two primary outcome measures, composite end-points of incident  
47 major adverse CVD-related events and CVD-related risk factors will be treated as binary  
48 outcomes collected  $\sim 36$  during the pre-intervention period and at 36 time points after the  
49 intervention (i.e. trail expansion), following Cochrane recommendations<sup>35</sup>. There will be a  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 two-year<sup>35</sup> lag incorporated into the time series reflecting the time during which the trails were  
4 being constructed. These time points reflect extensive literature showing that CVD-related  
5 behaviours<sup>62,63</sup> and endpoints vary seasonally<sup>64,65</sup> and that the impact of natural experiments  
6 requires several years to be detected at the population level<sup>28,35,37</sup>.  
7  
8  
9

### 10 11 *Time Series Analyses*

12  
13  
14 We will use two different time series methods to estimate the effect of the intervention on  
15 CVD-related end-point incident rates in treatment neighbourhoods relative to trends among the  
16 comparison neighbourhoods. First, a multi-group segmented regression of interrupted time series  
17 data will be used to assess the effect of the intervention on CVD-related incidence, both  
18 immediately (change in level) and over time (change in trend) by creating indicator variables as  
19 described elsewhere<sup>37,40</sup>. The level will be the base rate of CVD-related end-points at the  
20 beginning of the pre-intervention period (2000) and the value immediately following each  
21 change point at which successive segments join until 2010. The trend is the rate of change of  
22 CVD-related end-points (in other words, the slope) during a segment. Autoregressive errors will  
23 be modeled to account for correlated outcomes.  
24  
25  
26  
27  
28  
29  
30  
31

### 32 *Autoregressive integrated moving average*

33  
34  
35 An autoregressive integrated moving average (ARIMA) model will be fitted for the CVD  
36 incidence time series by using the standard approach for identification, estimation, and  
37 checking<sup>66</sup>. Trend and periodic seasonal terms will be applied to the entire study period (January  
38 2000 to July 2019). A separate ARIMA model will also be built for the pre-intervention period to  
39 forecast CVD evolution of the treated neighbourhoods. The number of CVD end-points  
40 prevented by the intervention will be estimated by calculating the difference between the  
41 predicted number and the observed number of cases. Should we encounter difficulty fitting an  
42 ARIMA model to a relatively small dataset, we will rely on exponential smoothing models or the  
43 Holt Winters Algorithm<sup>66</sup>. Although they require larger sample sizes, these methods are ideal for  
44 this project as (1) they permit a variety of different types of intervention effects to be modeled  
45 explicitly, and (2) they are well suited to forecasting future trends.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

### *Cost-Benefit analysis*

The cost-benefit analysis will focus on describing the “value for money” of the intervention. The objective of the economic analysis is to compare the cost and effect of the treatment group relative to the comparison group data collected in the study<sup>67</sup>. To align with the effectiveness analysis, the primary outcome variable in the economic analysis will be a composite endpoint of incident composite CVD-related end-points, similar to previous studies by one of the team members<sup>67-69</sup>. Costs for each participant will include those associated with the intervention (e.g., trail construction and maintenance costs) and health service utilization obtained from administrative data. From the perspective of the public payers (provincial and federal governments), we will conduct the economic analysis using the net benefit regression framework<sup>70,71</sup> which enables an adjustment for potential confounders. The main output of the economic analysis is the incremental net benefit of the treatment relative to the comparison group. In addition, we will estimate incremental cost-effectiveness ratios which will represent an incremental cost per one incident CVD end-point prevented or one CVD-related co-morbidity prevented. Furthermore, as there are more than one public payer for this intervention (e.g., Government of Winnipeg, Government of Manitoba), we will conduct separate analyses for each relevant perspective to assess the “value for money” specifically to each payer. We will characterize the uncertainty of our findings using a cost-effectiveness acceptability curve and 95% confidence interval. In addition, we will explore the possibility of building a decision analytic model which will examine the potential long-term economic impact of the intervention after the study period<sup>72</sup>. This economic model will use various data sources to estimate costs including the study<sup>73,74</sup>, published literature<sup>67-69</sup>, and expert opinion.

**Ethical Approval:** All aspects of the study design have been approved by the Biomedical Research Ethics Board at the University of Manitoba (Approval ID: REB\_HS20928 (H2017232)) and the Health Information Privacy Committee within the Province of Manitoba (Approval ID: HIPC - 2019/2020-05)

### **Discussion**

1  
2  
3 The proposed natural experimental study will fill a large gap in our understanding of the impacts  
4 of changes to the built environment on CVD-related outcomes. Specifically, we will provide  
5 critical experimental evidence for the impact of changes to urban spaces for recreational physical  
6 activity and active transportation on CVD-related morbidity and mortality. Additionally, to  
7 support evidence for future policies relating to urban activity corridors, we will also provide an  
8 estimate for the cost-effectiveness of large urban trail networks within cities.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

For peer review only

## DECLARATIONS

**Ethics approval and consent to participate:** This study was approved by the Biomedical Research Ethics Board at the University of Manitoba (H2017:232) and the Health Information Privacy Committee at the Winnipeg Regional Health Authority (HIPC - 2019/2020-05).

**Competing Interests:** The authors declare that they have no competing interests.

**Funding:** Funding for this project was provided by an operating grant from the Heart and Stroke Foundation of Canada (G-17-0018638) and the Canadian Institutes of Health Research (PJT-153449; CPP-137910). Funding bodies were not involved in the study design, conduct, interpretation or manuscript preparation for this project.

**Author Contributions:** All authors contributed to the study and manuscript in alignment with current ICMJE guidelines. The study was conceived by JM, AS and EH. JM and EH are the principal investigators on the original funded grant. EH, AS, GB, KR, LR, BS, WI and JM participated in designing the study and submitting the original grant. JM and SW were involved in recruiting the City of Winnipeg to share data. EH, AS, KR and JM designed the field data collection processes. EM is leading the geomapping of trail users and interpretation of gentrification data. WI is leading the cost effectiveness analyses of the study and SW is providing data for these analyses. AS, NB and JM are involved in data cleaning and verification. EH, NB and JM drafted the original manuscript. All authors contributed to critically revising the manuscript for important intellectual content, gave their final approval and agreed to be accountable for all aspects of the work, and they will participate in future interpretation of the data and drafting of further manuscripts arising from this work.

## References

1. Sallis JF, Bull F, Guthold R, et al. Progress in physical activity over the Olympic quadrennium. *Lancet* 2016.
2. Sallis JF, Floyd MF, Rodriguez DA, Saelens BE. Role of built environments in physical activity, obesity, and cardiovascular disease. *Circulation* 2012;125:729-37.
3. Meijer M, Rohl J, Bloomfield K, Grittner U. Do neighborhoods affect individual mortality? A systematic review and meta-analysis of multilevel studies. *Soc Sci Med* 2012;74:1204-12.
4. Frank LD, Kavage, S., Devlin, A. Health and the Built Environment: A Review 2012.
5. McCormack GR, Shiell A. In search of causality: a systematic review of the relationship between the built environment and physical activity among adults. *Int J Behav Nutr Phys Act* 2011;8:125.
6. Ferdinand AO, Sen B, Rahrkar S, Engler S, Menachemi N. The relationship between built environments and physical activity: a systematic review. *Am J Public Health* 2012;102:e7-e13.
7. Medicine Io. Bringing Public Health into Urban Revitalization: Workshop Summary. Bringing Public Health into Urban Revitalization: Workshop Summary. Washington (DC)2015.
8. Gascon M, Vrijheid M, Nieuwenhuijsen MJ. The Built Environment and Child Health: An Overview of Current Evidence. *Curr Environ Health Rep* 2016;3:250-7.
9. Mayne SL, Auchincloss AH, Michael YL. Impact of policy and built environment changes on obesity-related outcomes: a systematic review of naturally occurring experiments. *Obes Rev* 2015;16:362-75.
10. Sallis JF, Cerin E, Conway TL, et al. Physical activity in relation to urban environments in 14 cities worldwide: a cross-sectional study. *Lancet* 2016;387:2207-17.
11. Floyd MF, Spengler JO, Maddock JE, Gobster PH, Suau LJ. Park-based physical activity in diverse communities of two U.S. cities. An observational study. *Am J Prev Med* 2008;34:299-305.
12. Li F, Harmer P, Cardinal BJ, Bosworth M, Johnson-Shelton D. Obesity and the built environment: does the density of neighborhood fast-food outlets matter? *Am J Health Promot* 2009;23:203-9.
13. Polsky JY, Moineddin R, Glazier RH, Dunn JR, Booth GL. Relative and absolute availability of fast-food restaurants in relation to the development of diabetes: A population-based cohort study. *Can J Public Health* 2016;107:5312.
14. Beale SJ, Bending MW, Trueman P, Naidoo B. Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal. *Eur J Public Health* 2012;22:869-73.
15. Guo JY, Gandavarapu S. An economic evaluation of health-promotive built environment changes. *Prev Med* 2010;50 Suppl 1:S44-9.
16. Ding D, Gebel K. Built environment, physical activity, and obesity: what have we learned from reviewing the literature? *Health Place* 2012;18:100-5.
17. Abadie A, Diamond, A., Hainmueller, J. Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California's Tobacco Control Program. *Journal of the American Statistical Association* 2010;105:493-505.
18. Amatya A, Bhaumik D, Gibbons RD. Sample size determination for clustered count data. *Stat Med* 2013;32:4162-79.
19. Bancroft C, Joshi S, Rundle A, et al. Association of proximity and density of parks and objectively measured physical activity in the United States: A systematic review. *Soc Sci Med* 2015;138:22-30.
20. Clark S, Bungum T, Shan G, Meacham M, Coker L. The effect of a trail use intervention on urban trail use in Southern Nevada. *Prev Med* 2014;67 Suppl 1:S17-20.
21. Creatore MI, Glazier RH, Moineddin R, et al. Association of Neighborhood Walkability With Change in Overweight, Obesity, and Diabetes. *JAMA* 2016;315:2211-20.



- 1  
2  
3 22. Finlayson GS, Lix LM, Roos LL. The Whole Is Greater Than the Sum of the Parts: Using Data Linkage  
4 and Cohort Designs to Create Data Synergy at MCHP. *Health Policy* 2011;6:83-5.
- 5 23. Fransoo RR, Martens PJ, Need to Know T, et al. The rising prevalence of asthma: true increase,  
6 diagnostic exchange or diagnostic accuracy? *Health Policy* 2013;8:27-34.
- 7 24. Martens PJ. Straw into Gold: Lessons Learned (and Still Being Learned) at the Manitoba Centre for  
8 Health Policy. *Health Policy* 2011;6:44-54.
- 9 25. Nickel NC, Chateau DG, Martens PJ, et al. Data resource profile: Pathways to Health and Social  
10 Equity for Children (PATHS Equity for Children). *Int J Epidemiol* 2014;43:1438-49.
- 11 26. Roos LL, Soodeen RA, Bond R, Burchill C. Working more productively: tools for administrative data.  
12 *Health Serv Res* 2003;38:1339-57.
- 13 27. Smith M, Roos LL, Burchill C. Expanding the data repository: new technology and resources for  
14 the 21st century. *Health Policy* 2011;6:104-6.
- 15 28. Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based quasi-experimental  
16 approach when randomisation is not an option: interrupted time series analysis. *BMJ* 2015;350:h2750.
- 17 29. Sims M, Maxwell R, Bauld L, Gilmore A. Short term impact of smoke-free legislation in England:  
18 retrospective analysis of hospital admissions for myocardial infarction. *BMJ* 2010;340:c2161.
- 19 30. Jandoc R, Burden AM, Mamdani M, Levesque LE, Cadarette SM. Interrupted time series analysis  
20 in drug utilization research is increasing: systematic review and recommendations. *J Clin Epidemiol*  
21 2015;68:950-6.
- 22 31. Clancy L, Goodman P, Sinclair H, Dockery DW. Effect of air-pollution control on death rates in  
23 Dublin, Ireland: an intervention study. *Lancet* 2002;360:1210-4.
- 24 32. Law MR, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer  
25 advertising for clopidogrel in Medicaid. *Arch Intern Med* 2009;169:1969-74.
- 26 33. McAlister FA, Bakal JA, Majumdar SR, et al. Safely and effectively reducing inpatient length of stay:  
27 a controlled study of the General Internal Medicine Care Transformation Initiative. *BMJ Qual Saf*  
28 2014;23:446-56.
- 29 34. Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the management  
30 and outcomes of hypertension in the United Kingdom: interrupted time series study. *BMJ* 2011;342:d108.
- 31 35. EPOC-Cochrane. EPOC- Criteria for including interrupted time series analyses.  
32 <http://epoccochrane.org/sites/epoccochrane.org/files/uploads/inttimepdf> 1998.
- 33 36. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health  
34 technology assessment: lessons from two systematic reviews of behavior change strategies. *Int J Technol*  
35 *Assess Health Care* 2003;19:613-23.
- 36 37. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted  
37 time series studies in medication use research. *J Clin Pharm Ther* 2002;27:299-309.
- 38 38. von Hippel P, Benson R. Obesity and the natural environment across US counties. *Am J Public*  
39 *Health* 2014;104:1287-93.
- 40 39. (EPOC). EPaOoC. Interrupted time series (ITS) analyses. Available at:  
41 <http://epoc.cochrane.org/epoc-specific-resources-review-authors> Oslo: Norwegian Knowledge Centre  
42 for the Health Services 2013.
- 43 40. Linden A, Adams JL. Applying a propensity score-based weighting model to interrupted time series  
44 data: improving causal inference in programme evaluation. *J Eval Clin Pract* 2011;17:1231-8.
- 45 41. Distasio J, Kaufman, A. The Divided Priarie City: Income Inequality among Winnipeg's  
46 Neighbourhoods: Institute for Urban Studies, University of Winnipeg; 2015.
- 47 42. Fransoo R, Martens, P., Prior H., Burchill, C., Koseva, I., Bailly A. The 2013 RHA Health Indicators  
48 Atlas. [http://mchp-appserv.cpe.umanitoba.ca/reference/RHA\\_2013\\_web\\_version.pdf](http://mchp-appserv.cpe.umanitoba.ca/reference/RHA_2013_web_version.pdf): University of  
49 Manitoba; 2013.
- 50  
51  
52  
53  
54  
55  
56  
57

- 1
- 2
- 3
- 4 43. Lix LM, Yogendran MS, Shaw SY, Burchill C, Metge C, Bond R. Population-based data sources for chronic disease surveillance. *Chronic Dis Can* 2008;29:31-8.
- 5
- 6 44. Marrie RA, Fisk J, Tremlett H, et al. Differing trends in the incidence of vascular comorbidity in MS and the general population. *Neurol Clin Pract* 2016;6:120-8.
- 7
- 8 45. Ermagun AL, G.; Loh, T.H. . Urban Trails and Demand Response to Weather Variations. *Transp Res Part D Transp Environ* 2018;63:404-20.
- 9
- 10 46. Lix LM, Kuwornu JP, Kroeker K, et al. Estimating the completeness of physician billing claims for diabetes case ascertainment using population-based prescription drug data. *Health Promot Chronic Dis Prev Can* 2016;36:54-60.
- 11
- 12 47. Lindsey G PM, Hankey S. The Minnesota Bicycle and Pedestrian Counting Initiative: Implementation Study. In: Management MDoT-OoTS, ed. St. Paul, Minnesota: University of Minnesota; 2015.
- 13
- 14 48. Budowski A. Developing Expansion Factors to Estimate Cyclist Seasonal Average Daily Traffic in Winnipeg, MB. Winnipeg, Manitoba: University of Manitoba; 2015.
- 15
- 16 49. Chateau D, Metge C, Prior H, Soodeen RA. Learning from the census: the Socio-economic Factor Index (SEFI) and health outcomes in Manitoba. *Can J Public Health* 2012;103:S23-7.
- 17
- 18 50. Lees L, Slater T, Wyly E. The Birth of Gentrification. *Gentrification*. New York, NY: Taylor and Francis Group, LLC; 2013:3-38.
- 19
- 20 51. Kavanagh A, Bentley RJ, Turrell G, Shaw J, Dunstan D, Subramanian SV. Socioeconomic position, gender, health behaviours and biomarkers of cardiovascular disease and diabetes. *Soc Sci Med* 2010;71:1150-60.
- 21
- 22 52. Mackenbach JP, Cavelaars AE, Kunst AE, Groenhouf F. Socioeconomic inequalities in cardiovascular disease mortality; an international study. *Eur Heart J* 2000;21:1141-51.
- 23
- 24 53. Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. *Am J Public Health* 1992;82:816-20.
- 25
- 26 54. Lysy Z, Booth GL, Shah BR, Austin PC, Luo J, Lipscombe LL. The impact of income on the incidence of diabetes: a population-based study. *Diabetes Res Clin Pract* 2013;99:372-9.
- 27
- 28 55. Lipscombe LL, Austin PC, Manuel DG, Shah BR, Hux JE, Booth GL. Income-related differences in mortality among people with diabetes mellitus. *CMAJ* 2010;182:E1-E17.
- 29
- 30 56. Brook JR, Setton EM, Seed E, Shooshtari M, Doiron D, Consortium CTCUEHR. The Canadian Urban Environmental Health Research Consortium - a protocol for building a national environmental exposure data platform for integrated analyses of urban form and health. *BMC Public Health* 2018;18:114.
- 31
- 32 57. Pattanayak CW, Rubin DB, Zell ER. [Propensity score methods for creating covariate balance in observational studies]. *Rev Esp Cardiol* 2011;64:897-903.
- 33
- 34 58. Donner A, Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. London, ON: Arnold; 2000.
- 35
- 36 59. Fransoo R, Martens, P., Burland, E., Prior H., Burchill, C. *The Need to Know Team*. Manitoba RHA Indicators Atlas 2009. Elnnipeg, MB: University of Manitoba; 2009.
- 37
- 38 60. Pell JP, Haw S, Cobbe S, et al. Smoke-free legislation and hospitalizations for acute coronary syndrome. *N Engl J Med* 2008;359:482-91.
- 39
- 40 61. MacDonald JM, Stokes RJ, Cohen DA, Kofner A, Ridgeway GK. The effect of light rail transit on body mass index and physical activity. *Am J Prev Med* 2010;39:105-12.
- 41
- 42 62. Schaefer L, Plotnikoff RC, Majumdar SR, et al. Outdoor time is associated with physical activity, sedentary time, and cardiorespiratory fitness in youth. *J Pediatr* 2014;165:516-21.
- 43
- 44 63. Shephard RJ, Aoyagi Y. Seasonal variations in physical activity and implications for human health. *Eur J Appl Physiol* 2009;107:251-71.
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57

- 1  
2  
3 64. Danet S, Richard F, Montaye M, et al. Unhealthy effects of atmospheric temperature and pressure  
4 on the occurrence of myocardial infarction and coronary deaths. A 10-year survey: the Lille-World Health  
5 Organization MONICA project (Monitoring trends and determinants in cardiovascular disease). *Circulation*  
6 1999;100:E1-7.  
7  
8 65. Group TE. Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular  
9 disease, respiratory disease, and all causes in warm and cold regions of Europe. The Eurowinter Group.  
10 *Lancet* 1997;349:1341-6.  
11 66. Brockwell PJ. DR. Introduction to time series and forecasting. 2nd ed. New York, NY: Springer;  
12 2001.  
13 67. Tricco AC, Cogo E, Isaranuwatthai W, et al. A systematic review of cost-effectiveness analyses of  
14 complex wound interventions reveals optimal treatments for specific wound types. *BMC Med* 2015;13:90.  
15 68. Marsh JD, Birmingham TB, Giffin JR, et al. Cost-effectiveness analysis of arthroscopic surgery  
16 compared with non-operative management for osteoarthritis of the knee. *BMJ Open* 2016;6:e009949.  
17 69. Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting  
18 versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-  
19 analysis. *BMJ* 2014;349:g5459.  
20 70. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something  
21 blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. *Health Econ*  
22 2002;11:415-30.  
23 71. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup  
24 analysis for non-censored cost-effectiveness data. *Health Econ* 2004;13:461-75.  
25 72. Drummond MF, Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. *Methods for the*  
26 *economic evaluation of health care programmes*. Oxford, UK: Oxford university press.; 2015.  
27 73. Cui Y, Doupe M, Katz A, Nyhof P, Forget EL. Economic evaluation of Manitoba Health Lines in the  
28 management of congestive heart failure. *Healthc Policy* 2013;9:36-50.  
29 74. Forget EL. New questions, new data, old interventions: the health effects of a guaranteed annual  
30 income. *Prev Med* 2013;57:925-8.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tables and Figures

Figure 1. Map of Trail Locations within Winnipeg, Manitoba Canada as of 2016

Table 1. Details of the intervention: New Urban Trails

Table 2: Outcome Measures

Table 3: Potential sources of confounding between intervention and control arms that are available within linked databases.

For peer review only

Table 1. Details of the intervention: New Urban Trail Greenways

Variable	Northeast Pioneers	Yellow Ribbon	Bishop Grandin	Transcona Trail
Original Land Use	Converted rail line	Paved grassland	Paved grassland	Paved grassland / industrial re-appropriation
Const. Start Date	Summer '07	Summer '09	Summer '08	Summer '10
Completion date	~Autumn '12	~Autumn '11	~Autumn '10	~Autumn '10
Const. Start Date	Summer '07	Summer '09	Summer '08	Summer '10
Completion date	~Autumn '12	~Autumn '11	~Autumn '10	~Autumn '10
Distance of Trail	6.5km	5km	8km	6.7 km
Dissemination areas within 800m access	103	48	243	45
Estimated pop. within 800m	53 308	20 376	153 015	21 915
Immediate adjacent environment	Trail located between two major roadways	Greenspace, neighbourhood, airport	Major roadway and neighbourhoods/business parks	Neighbourhood, grassland, business park
Mixed land use	High (homes, schools, shopping, recreation, parks)	Medium (homes, schools, parks)	High (homes, schools, shopping, parks)	Medium (homes, shopping, parks)

Table 2. Outcome Measures in the natural experiment of urban trail expansion

Category	Variable	Outcome	Definition	Source		
Primary	Major adverse cardiovascular events (MACE) - Composite	CVD-related mortality	Death in vital statistics mortality data with most responsible cause of death coded as CHF, IHD or stroke.	Vital statistics mortality		
		Ischemic heart disease	-1+ Inpatient Hospitalizations -2+ Physician visits in 5 years -1 Physician Visit & 2+ Rx in 5 years	Hospital abstracts, Medical claims, DPIN prescription dispensations		
		Congestive heart failure	-1+ inpatient visits or 2+ physician visits	Hospital abstracts, Medical claims		
		Cerebrovascular event	- 1+ Inpatient Hospitalizations - death in hospital	Hospital abstracts		
		Secondary	CVD-related risk factors - Composite	Hypertension	-1+ Inpatient Hospitalizations -2+ Physician visits in 2 years	Hospital abstracts, Medical claims
				Diabetes	-1+ Inpatient Hospitalizations -2+ Physician visits in 3 years -2+ Rx for glucose lowering agents in 3 years,	Hospital abstracts, Medical claims, Prescription dispensations
Dyslipidemia	-1+ Hospitalization -2+ Physician visits in 3 years -2+ Rx for statins in 3 years			Hospital abstracts, Medical claims, Prescription dispensations		
Secondary	Trail use	Bicycle counts		Eco-Counter Magnetic Zelts		

located beneath  
greenways

Exploratory	Income	Household	Self-reported	Intercept surveys
	Ethnicity		Self-reported	
	Gender	Male, female, other	Self-reported	
	Residence	Postal code	Self-reported	
	Weekly use	Visits/week	Self-reported	
	Time on trail	Minutes/use	Self-reported	

---

CHF = congestive heart failure; CVD = cardiovascular disease; ICD = international classification code; IHD = ischemic heart disease, Rx = prescription


Table 3. Potential sources of confounding between intervention and control groups that are available within linked databases

Category	Variable	Definition	Source	Years available
Socio-economic status	Income	Household income	Census	2006 and 2016
	SEFI	Material and social deprivation	MCHP repository	Annual
Demographics	Age		Census	2006 and 2016
	Sex		Census	2006 and 2016
	Ethnicity		Census	2006 and 2016
	Immigration status		Census	2006 and 2016
Gentrification	Change in mean age neighbourhood	Taxation valuation of value of property	City of Winnipeg	2008 to 2018
	Property value			
Built environmental factors that support physical activity	Greenspace	Distance to park (kms)	DMTI/CANUE	2006 and 2016
	Walkability	Population density, mixed land use, connectivity	CAN-ALE (CANUE)	2006 and 2016
	Fitness/Recreation Centres	Distance to centre	CANUE	2006 and 2016

SEFI = socioeconomic factor index; DMTI = Digital Mapping company name; MCHP = Manitoba Centre for Health Policy; kms = kilometers



Figure 1. Map of Trail Locations within Winnipeg, Manitoba Canada as of 2016



Complete trail map includes old (green lines) and new trails/greenways (red lines), comprising ~400km of total trails. Large red trails are “high dose” multi-use trails that extend across multiple neighbourhoods and accessible 12 months of the year (A= Northeast Pioneers Greenway; B= Yellow Ribbon Greenway; C= Transcona Trail & D= Bishop Grandin Greenway). Other green lines represent medium or low impact bike trails or gravel trails not used in winter or only for active commuting. Note large red areas that have not received trails.

Appendix sTable 1. Diseases or risk factors classification and corresponding International Classification of Disease (ICD) codes, in alphabetical order.

INDICATION	ICD TITLE	ICD 10 CODE	ICD 9 CODE
<b>Diagnoses indicative of a cardiovascular disease endpoint – Primary outcome</b>			
Ischemic heart disease	Angina pectoris	I20	413
	Acute myocardial infarction	I21	410, 434.91
	Subsequent myocardial infarction	I22	412
	Other acute ischaemic heart diseases	I24	411
	Chronic ischaemic heart disease	I25	414
Cardiac arrest	Cardiac arrest	I46	427.5
Heart failure	Heart failure	I50	428
Cerebral infarction	Cerebral infarction	I63	433, 434, 435
	Stroke	I64	437.0, 437.1, 437.3
<b>Diagnoses indicative of a cardiovascular disease risk factor – Secondary Outcome</b>			
Diabetes	Diabetes	E11	250
Hyperlipidemia	Dyslipidemia	E78	272.3, 272.5, 272.6
Hyperlipidemia	Pure hypercholesterolaemia	E78.0	272.0
	Pure hyperglyceridaemia	E78.1	272.1
	Mixed hyperlipidaemia	E78.2	272.2
	Hyperlipidaemia, unspecified	E78.5	272.4
Hypertension	Essential (primary) hypertension	I10	401, 459.3
	Hypertensive heart disease	I11	402

	Hypertensive renal disease	I12	403
	Hypertensive heart and renal disease	I13	404
<b>Diagnoses leading to exclusion from the cohort</b>			
Cardiomyopathy	Endocardial fibroelastosis	I42.4	425.3
	Endomyocardial disease	I42.3	425.0
	Congenital cardiomyopathy	I42.8	Not applicable
	Familial cardiomyopathy	I42.9	425.9
Congenital malformation of circulatory system	Congenital malformations of the circulatory system	Q20 to Q28	745, 746, 747, 759.9
Cystic fibrosis	Cystic fibrosis	E84	277.0
<b>Ineligible diagnoses (not considered as outcome, but did not warrant exclusion of the participant)</b>			
Other cardiovascular problems (eg cause is viral, genetic, alcoholic, etc.)	Other cardiovascular problems	E78.7, E78.8	424.9, 425.2, 425.5, 425.7, 425.8, 425.9
Arrhythmia*	Cardiac dysrhythmias	I49	427 excluding 427.5 (see Cardiac arrest)
	Abnormalities of heart beat	R00 to 03	785.3

\*Arrhythmias were ineligible because their definition in administrative databases has not yet been validated and a local pediatric cardiologist informed us that most dysrhythmia diagnoses or referrals would not be considered cardiovascular disease or risk.